澳大利亚青少年接种脑膜炎球菌C结合疫苗后的抗体持久性。

Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.

作者信息

Perrett Kirsten P, Richmond Peter C, Borrow Ray, Nolan Terry, McVernon Jodie

机构信息

From the *Vaccine and Immunisation Research Group (VIRGo), Murdoch Childrens Research Institute and Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia, †School of Paediatrics and Child Health, University of Western Australia, Telethon Institute for Child Health Research, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; and ‡Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, Greater Manchester, United Kingdom.

出版信息

Pediatr Infect Dis J. 2015 Mar;34(3):279-85. doi: 10.1097/INF.0000000000000541.

DOI:10.1097/INF.0000000000000541

PMID:25742078

Abstract

BACKGROUND

In Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence, MenC disease incidence plummeted and remains low. However, individual protection following MenC conjugate vaccination, particularly in young children, may be short-lived. We investigated the persistence of MenC serum bactericidal antibody (SBA) titers in adolescents, more than 7 years after a single "catch-up" dose of MenC conjugate vaccine. We also investigated their exposure and susceptibility to meningococcal serogroups A, W and Y.

METHODS

MenC SBA titers and Men A, C, W and Y IgG geometric mean concentration were measured in 240 healthy 11- to 16-year-old adolescents. The correlate of protection was an rSBA titer of ≥8.

RESULTS

An rSBA≥8 was observed in 105 [44% (95% confidence interval {CI}, 37-50%)] of 240 adolescents (mean age, 13.2 years, mean interval since MenC immunization, 8.2 years). The proportion with an rSBA≥8, geometric mean rSBA titer and geometric mean IgG concentration increased with age, from 22% to 75%, 3.7 to 33.4 and 0.13 to 0.52 μg/mL, in participants who received MenC vaccine at mean age 2.8 to 7.5 years, respectively. Natural acquired antibody to Men A, W and Y was low with IgG geometric mean concentrations of 1.26, 0.38 and 0.47 μg/mL, respectively.

CONCLUSIONS

More than half of Australian adolescents have inadequate serological protection against MenC disease and low natural immunity to MenA, W and Y.

摘要

背景

在澳大利亚，自引入针对幼儿的C群脑膜炎球菌（MenC）结合疫苗并在青少年中开展补种免疫后，MenC疾病发病率急剧下降且维持在低水平。然而，MenC结合疫苗接种后的个体保护作用，尤其是在幼儿中，可能持续时间较短。我们调查了在单次“补种”MenC结合疫苗7年多后青少年中MenC血清杀菌抗体（SBA）滴度的持久性。我们还调查了他们对A、W和Y群脑膜炎球菌的暴露情况及易感性。

方法

对240名11至16岁健康青少年测量MenC SBA滴度以及A、C、W和Y群脑膜炎球菌IgG几何平均浓度。保护相关性指标为rSBA滴度≥8。

结果

240名青少年（平均年龄13.2岁，自MenC免疫后的平均间隔时间为8.2年）中有105名（44%[95%置信区间{CI}，37 - 50%]）的rSBA≥8。在平均年龄2.8至7.5岁时接种MenC疫苗的参与者中，rSBA≥8的比例、rSBA几何平均滴度和IgG几何平均浓度随年龄增加，分别从22%增至75%、3.7增至33.4以及0.13增至0.52μg/mL。对A、W和Y群脑膜炎球菌的自然获得性抗体水平较低，IgG几何平均浓度分别为1.26、0.38和0.47μg/mL。